Discussion about this post

User's avatar
Christina Ren, MS, CGC's avatar

The rate of improvement for cancer liquid biopsies is astonishing. Two questions:

1. Based on your description of MRD and its lower tumor fraction, it seems technically more challenging than cancer screening?

2. In your view, what company(ies) shows the most promise in translating this type of research for commercial use in the clinic?

Expand full comment
Will's avatar

Great dive into the details.

I think doing a better job detecting residual disease would be a big advance if it lets less patients get treated (eg is more specific than current standard of care.) Doing really early detection of cancer before overt disease is also a big deal.

I wonder how the clinical trials for this stuff would look.

Expand full comment
4 more comments...

No posts